[18F]MNI-1126

N/A

Report date: 2025/12/02 10:04:55

NME

Base Information

Drug Name[18F]MNI-1126

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentSmall molecules > Heterocyclic drugs +[5]

Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersSynaptic vesicle glycoprotein 2A binders

TargetsSynaptic vesicle glycoprotein 2A

Therapy Area/IndicationsAlzheimer DiseaseParkinson Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInvicro Llc

China Registration ClassN/A

Develop Information

Active CompaniesInvicro Llc

Inactive CompaniesN/A

Active IndicationsAlzheimer DiseaseParkinson Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A